Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 10;13(12):e081650.
doi: 10.1136/bmjopen-2023-081650.

Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot

Chloe Beard  1 , Chris A Rogers  1 , Leah Fleming  1 , John Conibear  2 , Matthew Evison  3 , Thomas Newsom-Davis  4 , Tara Barwick  5 , Nicola Mills  6 , Elizabeth A Stokes  7 , Paulo De Sousa  8 , Tim Batchelor  9 , Janette Rawlinson  10 , Sarah Baos  1 , Rosie Harris  1 , Eric Lim  11
Affiliations

Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot

Chloe Beard et al. BMJ Open. .

Abstract

Introduction: Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it. Therefore, residual disease management varies across the UK, with some patients receiving only maintenance systemic anti-cancer treatment while others receive local consolidative treatment (LCT), alongside maintenance systemic anti-cancer treatment. LCT can be a combination of surgery, radiotherapy and/or ablation to remove all remaining cancer within the lung and throughout the body. This is intensive, expensive and impacts quality of life, but we do not know if it results in better survival, nor the extent of impact on quality of life and what the cost might be for healthcare providers. The RAMON study (RAdical Management Of Advanced Non-small cell lung cancer) will evaluate the acceptability, effectiveness and cost-effectiveness of LCT versus no LCT after first-line systemic treatment for advanced lung cancer.

Methods and analysis: RAMON is a pragmatic open multicentre, parallel group, superiority randomised controlled trial. We aim to recruit 244 patients aged 18 years and over with advanced non-small-cell lung cancer from 40 UK NHS hospitals. Participants will be randomised in a 1:1 ratio to receive LCT alongside maintenance treatment, or maintenance treatment alone. LCT will be tailored to each patient's specific disease sites. Participants will be followed up for a minimum of 2 years. The primary outcome is overall survival from randomisation.

Ethics and dissemination: The West of Scotland Research Ethics Committee (22/WS/0121) gave ethical approval in August 2022 and the Health Research Authority in September 2022. Participants will provide written informed consent before participating in the study. Findings will be presented at international meetings, in peer-reviewed publications, through patient organisations and notifications to patients.

Trial registration number: ISRCTN11613852.

Keywords: Lung Diseases; Thoracic surgery; adult oncology; radiation oncology; randomized controlled trial; respiratory tract tumours.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors received support from the National Institute for Health and Care Research for the project associated with this manuscript, which was paid to their employing institution. EL reports personal fees from Abbott Molecular, AstraZeneca, Glaxo Smith Kline, Pfizer, Norvatis, Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, Ethicon, and AstraZeneca, and grants from ScreenCell, Clearbridge Biomedics, Illumina, and Guardant Health. PDS reports personal fees from Vitae Professionals. JR reports personal and travel fees from NCRI Lung Advanced disease subgroup, ELF lung cancer patient advisory group, BTOG, Clinical expert group lung cancer, WM Cancer Alliance lung cancer and mesothelioma EAG (as a patient representative). TND reports personal fees from AstraZenca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche, Takeda, BMS, Eli-Lilly, Novartis, and Pfizer.

Figures

Figure 1
Figure 1
Study schema. SACT, systemic anti-cancer treatment.
See this image and copyright information in PMC

References

    1. Royal College of Physicians . National Lung Cancer Audit annual report 2018 (for the audit period 2017). London: Royal College of Physicians, 2019.
    1. Dingemans A-M, Hendriks LEL, Berghmans T, et al. Definition of synchronous Oligometastatic non-small cell lung cancer-A consensus report. J Thorac Oncol 2019;14:2109–19. 10.1016/j.jtho.2019.07.025 - DOI - PubMed
    1. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol 2018;4:e173501. 10.1001/jamaoncol.2017.3501 - DOI - PMC - PubMed
    1. Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative radiotherapy versus standard of care palliative treatment in patients with Oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051–8. 10.1016/S0140-6736(18)32487-5 - DOI - PubMed
    1. Conibear J, Chia B, Ngai Y, et al. Study protocol for the SARON trial: a Multicentre, randomised controlled phase III trial comparing the addition of stereotactic Ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for Oligometastatic non-small cell lung cancer. BMJ Open 2018;8:e020690. 10.1136/bmjopen-2017-020690 - DOI - PMC - PubMed

Publication types

Associated data